



## New frontiers in flavin-dependent monooxygenases

Renata A.G. Reis <sup>a</sup>, Hao Li <sup>a</sup>, Maxim Johnson <sup>a</sup>, Pablo Sobrado <sup>a,b,\*</sup>

<sup>a</sup> Department of Biochemistry, Blacksburg, VA, 24061, USA

<sup>b</sup> Center for Drug Discovery, Virginia Tech, Blacksburg, VA, 24061, USA



### ARTICLE INFO

#### Keywords:

Flavin motions  
Oxygen activation  
Conformational changes  
Antibiotics  
Monooxygenation  
Homolytic bond cleavage  
Drug target

### ABSTRACT

Flavin-dependent monooxygenases catalyze a wide variety of redox reactions in important biological processes and are responsible for the synthesis of highly complex natural products. Although much has been learned about FMO chemistry in the last ~80 years of research, several aspects of the reactions catalyzed by these enzymes remain unknown. In this review, we summarize recent advancements in the flavin-dependent monooxygenase field including aspects of flavin dynamics, formation and stabilization of reactive species, and the hydroxylation mechanism. Novel catalysis of flavin-dependent *N*-oxidases involving consecutive oxidations of amines to generate oximes or nitrones is presented and the biological relevance of the products is discussed. In addition, the activity of some FMOs have been shown to be essential for the virulence of several human pathogens. We also discuss the biomedical relevance of FMOs in antibiotic resistance and the efforts to identify inhibitors against some members of this important and growing family enzymes.

### 1. Introduction

Flavin-dependent monooxygenases (FMOs)<sup>1</sup> use oxygen and an external reductant, such as NADPH, to oxygenate a large number of compounds. The reaction involves the insertion of one oxygen atom into an organic substrate, while the other oxygen atom is reduced to water [1,2].

FMOs catalyze a wide variety of redox reactions in important biological processes, such as in the transformation of xenobiotic compounds, in the detoxification of drugs, in the biosynthesis of antibiotics and hormones, and in the hydroxylation of amino acids [3,4]. In addition, the activity of FMOs has been exploited for the production of intermediate compounds for industrial processes. For example, FMOs are known to perform epoxidation of substituted alkenes, which is essential in the formation of enantiopure organic compounds that are widely used in the pharmaceutical industry [5]. In addition, FMOs are responsible

for the synthesis of highly complex natural products, some of which are potential new drugs for the treatment of cancers and bacterial and fungal infections [4,6,7]. This has led to an increase interest in the biological pathways responsible for the production of these compounds [8]. Biosynthetic gene clusters and characterization of enzymes in these pathways have revealed novel enzymatic functions, many of which are carried out by FMOs [8]. For instance, novel FMOs that perform double hydroxylation of aspartic acids in the biosynthesis of the antibiotic fosfazinomycin have been identified [9]. Similarly, the formation of oxime functional groups in the biosynthesis of caerulomycin A is also catalyzed by an FMO [10].


The catalytic cycle of FMOs can be simplified into two half-reactions: the reductive and oxidative half reactions (Fig. 1). These enzymes require a hydride equivalent from NAD(P)H to reduce the flavin and activate molecular oxygen. Oxygen activation involves a single electron transfer step that results in the formation of a flavin-semiquinone and a

**Abbreviations:** FMO, Flavin-dependent monooxygenase; Fl, flavin; FAD, flavin adenine dinucleotide; Fl<sub>4a</sub>-OOH, C4a-hydroperoxiflavin; NMOs, N-mono-oxygenases; BVMOs, Baeyer-Villiger monooxygenases; NADPH, reduced nicotinamide adenine dinucleotide phosphate; NADP<sup>+</sup>, oxidized nicotinamide adenine dinucleotide phosphate; PHBH, *p*-hydroxybenzoate hydroxylase; *p*-OHB, 4-hydroxybenzoate; APBS, Adaptive Poisson-Boltzmann Solver; PDB, Protein Data Bank; SKIES, solvent kinetic isotope effects; QM/MM, quantum mechanics/molecular mechanics; DFT, density functional theory; HRC-ET hydroxyl, radical-coupled electron transfer mechanism; SidA, siderophore A; Ktzl, *Kutzneria* sp. 744; PvdA, pyoverdine A from *Pseudomonas aeruginosa*; FzmM, fosfazinomycin M; CreE, caerulomycin E; CrmH, caerulomycin H; 2AEpN, 2-aminoethylphosphonate; TetX, tetracycline destructase; RIFMO, rifampicin monooxygenase; RIF, rifampicin; Kynureine 3-monooxygenase; HTS, high throughput screening; SQLE, squalene epoxidase; SQS, squalene synthase; EpnF, eponeymycin.

\* Corresponding author. Department of Biochemistry, Virginia Tech, Blacksburg, VA, 24061, USA.

E-mail address: [psobrado@vt.edu](mailto:psobrado@vt.edu) (P. Sobrado).

<sup>1</sup> We note that many publications referred to flavin-containing monooxygenases as FMOs. In this review we used this acronym to refer to the family of flavin-dependent monooxygenases.



**Fig. 1.** Cautious and bold mechanisms of flavin monooxygenases. A) The cautious mechanism follows a ping-pong mechanism as the reaction with oxygen occurs in the presence of the substrate and the absence of  $\text{NADP}^+$  (circled). B) The bold mechanism follows a sequential mechanism of substrate binding and the formation of  $\text{F}_{4\alpha}\text{-OOH}$  (circled) occurs in the absence of substrate. Reductive-half reaction is shown in yellow and the oxidative-half reaction in gray. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

superoxide radical pair that combine to form C(4a)-hydroperoxyflavin ( $\text{F}_{4\alpha}\text{-OOH}$ ), which is responsible for substrate oxidation [11]. FMOs are unique in their ability to form and stabilize  $\text{F}_{4\alpha}\text{-OOH}$  [12].  $\text{F}_{4\alpha}\text{-OOH}$  is tuned by the active site environment to catalyze the hydroxylation, epoxidation, or Baeyer–Villiger oxidation of a wide range of substrates [12].

FMOs are classified into eight distinct subclasses based on amino acid sequence and structural and biochemical properties. The eight subclasses (A–H) are divided into two groups based on mechanistic properties. Subclasses A, B, G, and H undergo reduction and oxidation by an electron donor within the same polypeptide chain and are known as single component monooxygenases. Subclasses C–F obtain the reduced flavin from a flavin oxidase enzyme. These are known as two-component monooxygenases [3,4].

This review aims to explore new frontiers in FMO catalysis and applications, with a focus on the biochemical, computational, and structural data of FMOs that hydroxylate N-atoms, also known as N-monooxygenases (NMOs). New insights into the mechanism of FMOs are described, including aspects of flavin conformational changes, formation and stabilization of  $\text{F}_{4\alpha}\text{-OOH}$ , and the mechanism of hydroxylation. Furthermore, we also discuss recently characterized reactions catalyzed by novel NMOs. Additionally, relevant bio-medicinal applications of FMOs, such as drug resistance and FMOs as targets in drug discovery, are examined.

## 2. New insights into the mechanism of action of FMOs

FMOs catalyze a complex reaction that involves not only coordination of the flavin and several substrates but also reduction and oxidation of cofactors and substrates within the same active site. Although much has been learned in the last ~80 years of research on FMO chemistry, several aspects of the reactions catalyzed by these enzymes remain unknown [1,4]. Specific flavin motion and conformational changes have been outlined in the past but have only been attributed to one specific group of FMOs. A combination of experimental and computational methods has been used to investigate the molecular details related to flavin dynamics [13,14], formation and stabilization of reactive species [15–17], and hydroxylation mechanism of FMOs [18]. Here, we describe our current understanding of recent data that provides new insights into the mechanism of action of FMOs with a specific focus on

recent discoveries from NMOs.

### 2.1. Flavin dynamics in FMOs

Flavins are well known for their remarkable chemical versatility. These cofactors are responsible for a variety of biological reactions that are derived from the chemical complexity of their catalytic center, the isoalloxazine ring system. The reactivity of the isoalloxazine ring is seen across an assortment of reactions catalyzed by flavoenzymes, including hydroxylation, hydration, desaturation, photochemistry, electron transfer, and oxygen activation [19–21]. It is well established that the protein matrix plays a major role in modulating the catalytic potential of the flavin cofactor, since free flavins are not capable of performing many of these reactions [22,23]. Understanding and predicting how flavin cofactor reactivity is modulated by the protein environment is still an active area of investigation [22].


Flavoenzymes have also been extensively studied to elucidate the mechanism of their conformational flexibility. It has been reported that conformational changes in the flavin cofactor itself are crucial to multiple steps in the catalytic cycle and these motions are accompanied by changes in protein conformation [24,25].

In FMOs, conformational changes of the flavin were first described in *p*-hydroxybenzoate hydroxylase (PHBH), followed by other related enzymes [24,26,27]. PHBH typifies the class A monooxygenases and has been extensively investigated by kinetic, spectroscopic, and crystallographic studies [25,28,29]. The mechanism of action of class A monooxygenases with oxygen has been described as the “cautious mechanism”, which is characterized by the release of  $\text{NADP}^+$  before the addition of oxygen (e.g., ping-pong kinetic mechanism) (Fig. 1A). The substrate to be hydroxylated (substrate henceforth) binds first and then the complex reacts with NAD(P)H. Substrate binding enhances the reaction with NAD(P)H by up to ~10<sup>5</sup>-fold [29]. The cautious mechanism lowers the risk of uncoupling (e.g., release of hydrogen peroxide without substrate hydroxylation), since the reaction of reduced flavin with oxygen to form the  $\text{F}_{4\alpha}\text{-OOH}$  occurs only when the substrate is present and poised for hydroxylation [2,11].

A key feature of the caution mechanism is that the motion of the flavin cofactor has been shown to be essential. The structural basis for the mobility of the flavin isoalloxazine ring was identified in PHBH based on structural analysis of complexes with 4-hydroxybenzoate (*p*-OHB) [30] (Fig. 2) and the analog 2,4-dihydroxybenzoate [24,26]. The structure of the PHBH-*p*-OHB complex has both *p*-OHB and the isoalloxazine ring in the active site (the “in” conformation) (Fig. 2). In the structure of PHBH with the 2,4-dihydroxybenzoate, the isoalloxazine ring occupies a position that exposes the re-face to the solvent (the “out” conformation) (Fig. 2). Structural and mechanistic studies have shown that binding and deprotonation of *p*-OHB and binding of NADPH triggers flavin motion from the protein interior (“in” conformation) to an exposed position in contact with the solvent (“out” conformation) where reduction takes place [25]. The active site is electropositive and induces the electron rich reduced flavin to the “in” conformation (Fig. 2). Thus, the movement from the “out” to the “in” conformation is coupled to flavin reduction.

The conformational adaptability of the flavin cofactor in the catalytic cycle provides suitable environments for the different steps of the reaction, effectively separating the reduction and oxidative half-reactions catalyzed by PHBH. The net conformational change of the flavin movement in PHBH, and other related enzymes, with the C(2) ribityl chain functioning as the pivot point, is a “waving” movement of 7–8 Å (Fig. 3C) [27]. In terms of the protein environment, it is also suggested that the movement of Tyr222 (numbering in PHBH from *Pseudomonas fluorescens* and *Pseudomonas aeruginosa*) away from the substrate aids in the displacement of the flavin [15]. This is supported by spectral and kinetic data collected on mutant enzymes PHBH Y222A and Y222V [31].

Class B monooxygenases were thought to utilize a different mechanism to prevent release of hydrogen peroxide. Members of this group are



**Fig. 2.** Flavin mobility in class A and class B FMOs. (A) Surface electrostatic potential representation of *p*-hydroxybenzoate hydroxylase (PHBH) in complex with 4-hydroxybenzoate showing the “in” FAD (yellow) and 2,4-dihydroxybenzoate showing the “out” FAD (orange). 4-hydroxybenzoate and 2,4-dihydroxybenzoate were omitted for clarity. (B) Surface electrostatic potential representation of SidA. Reduced FAD is shown in the “in” (gray) and oxidized FAD is shown in the “out” (yellow) conformations in the active site. The color scale goes from red to blue, corresponding respectively to  $-5$  and  $+5$   $k_BT/e$ . The surface electrostatic potential was calculated using the APBS plugin [32] for PyMOL to solve the linearized Poisson-Boltzmann equation at an ionic strength of 150 mM (NaCl), pH 7.0, a solvent radius of 1.4 Å, and its relative permittivity equal to 78. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

able to rapidly react with NAD(P)H. The reduced flavin then reacts with oxygen and the Fl<sub>4a</sub>-OOH is formed in the absence of substrate. In this case, the Fl<sub>4a</sub>-OOH is stabilized and ready for catalysis as it waits for the substrate to enter the active site. The half-life of Fl<sub>4a</sub>-OOH has been calculated to be several minutes to hours [33]. Because these enzymes form the intermediate regardless of the substrate’s presence, the mechanism has been referred to as the “bold mechanism” (Fig. 1B). It has been shown that the presence of NADP<sup>+</sup> is essential for the stabilization of Fl<sub>4a</sub>-OOH. In fact, NADP<sup>+</sup> is the last product to be released.

The first Baeyer-Villiger monooxygenase (BVMO) structure, which is a class B FMO, was solved in 2004 [34] and the first structure of a flavin-containing monooxygenase<sup>1</sup> was solved in 2006 [35]. These seminal works established the structural domains of this family of enzymes and shed light onto the complexity of the mechanism of action. The structures did not have substrates bound and only the structure of the flavin-containing monooxygenase was solved in complex with NADP<sup>+</sup>. NADP<sup>+</sup> was bound in an extended conformation and the nicotinamide ring was adjacent to the isoalloxazine ring; however, the NADP<sup>+</sup>-C4-atom was  $\sim 5$  Å away from the Fl-N5-atom and was not properly aligned for hydride transfer [36] (Fig. 4). Furthermore, the conformation of the nicotinamide ring was consistent with a hydride transfer from the proS position, which is in contrast with extensive biochemical data that suggests that this occurs from the proR-position (Fig. 4) [37–39]. The observed binding of NADP<sup>+</sup> led to different interpretations of its role in catalysis. One group suggested that hydride transfer occurred via the C2-position of the nicotinamide [35]. However, this possibility is not consistent with the mechanism of hydride transfer of NAD(P)H and kinetic isotopic data that shows that a hydride equivalent is transferred to the flavin from the C4-position [38]. It was also suggested that the observed binding of NADP<sup>+</sup> was one that occurred after hydride transfer and might represent the conformation involved in the stabilization of the Fl<sub>4a</sub>-OOH [40].

Several more structures of class B family members became available that support the so called “moonlighting” role of NAD(P)H in catalysis. Particularly informative were the structures of BVMO from *Thermobifida fusca* in different redox states [41] and the NMO ornithine hydroxylase, SidA, from *Aspergillus fumigatus* in complex with NADP<sup>+</sup> and ornithine in the oxidized (Fig. 3B), reduced, and re-oxidized states [36]. It was concluded that after flavin reduction, one of the key functions of NADP<sup>+</sup> was to interact with the Fl-N5-atom. When the flavin is in the oxidized form, the amine group of the nicotinamide functions as a hydrogen bond donor to the Fl-N5-atom. Upon reduction, the amide group flips  $\sim 180^\circ$ , allowing the carbonyl oxygen to function as a hydrogen bond acceptor and the flavin-N5H as the hydrogen bond donor (Fig. 4C). Further

structural, mechanistic, and biochemical studies were analyzed in terms of protein conformational changes that modulated binding of the nicotinamide ring in what has been referred to as the “cofactor sliding mechanism” [33,42–44].


Recently, a new crystal form of SidA revealed flavin conformational changes [14] (Fig. 3D) that were not observed in previous SidA structures [36]. Along with SidA, flavin mobility was also reported in Ktzl, an ornithine hydroxylase from the soil actinomycete *Kutzneria* sp. 744 [13, 45]. SidA and Ktzl share high levels of sequence homology, with 34% identity.

The flavin conformational changes in class B NMOs are different from what was previously described in class A monooxygenases (Fig. 3). While the flavin motion in class A monooxygenases occurs nearly within the plane of the isoalloxazine ring, in these ornithine hydroxylase NMOs, the flavin motion involves rotations around two dihedral angles that result in a more pronounced movement of the isoalloxazine moiety with the ribityl tail not being disturbed [14] (Fig. 3).

Flavin mobility in NMOs is best understood as adapting either an “in” or an “out” conformation in which the movement of FAD is thought to aid in the release of NADP<sup>+</sup> from the enzyme active site after turnover in preparation for a new catalytic cycle [13]. In the “out” position, the isoalloxazine system moves away from the active site and becomes exposed to the solvent where the *si*-face of the oxidized FAD can be seen stacking with a conserved tyrosine (Tyr341 in SidA and Tyr 276 in Ktzl). These Tyr are located in what has been called the Tyr-loop, which contains other residues that also undergo conformational changes (Fig. 5). After FAD reduction, the flavin cofactor moves back into the active site (“in” position) with the Tyr-loop rearranged by NAD(P)H binding.

Although the molecular nature of the flavin motion, as well as the Tyr loop, is similar in SidA and Ktzl, the factors determining flavin dynamics differ. It is suggested that for SidA, both NADP<sup>+</sup> binding and flavin reduction drives FAD into the “in” conformation. The main difference between SidA and Ktzl is found in the oxidized structures of both enzymes in the presence of NADP<sup>+</sup>. While the Ktzl-NADP<sup>+</sup> complex contains the oxidized FAD in the “out” position, the SidA-NADP<sup>+</sup> complex contains the oxidized FAD in the “in” position. However, in both structures, the Tyr-loop avoids steric clashes with NADP<sup>+</sup> by shifting away from the active site.

A new study on the kinetic and structural characterization of the SidA variant M101A provides another piece of evidence that supports the role of active site dynamics in controlling NADP<sup>+</sup> release in class B monooxygenases. Met101 was previously shown to change conformation upon reduction and contact the pyrimidine ring of FAD in the “in”



**Fig. 3.** Structures of PHBH and SidA. (A) Cartoon representation of the overall structure of class A FMO PHBH monomer (PDB ID: 1PBE) colored by domains (FAD binding domain in light blue, substrate binding domain in light pink and interface domain in orange). Stick representation of the FAD and 4-hydroxybenzoate, carbon atoms are colored in yellow and green, respectively. (B) Cartoon representation of the overall structure of class B FMO SidA monomer (PDB ID: 4B63) colored by domains (FAD binding domain in light blue, substrate binding domain in light pink and NADP(H) domain in green). Stick representation of the FAD, NADPH and ornithine, carbon atoms are colored in yellow, orange, and cyan, respectively. (C) Flavin mobility in class A FMOs. Overlaying the FAD “in” (yellow) (PDB ID: 1PBE) and “out” (orange) (PDB ID: 1DOD) states for class A monooxygenases showing the motion of the flavin along the isoalloxazine plane, resembling a “waving” motion. (D) Flavin mobility in class B FMOs. The “in” (gray) (PDB ID: 6X0J) and “out” (yellow) (PDB ID: 6X0H) conformation in class B NMOs occurs via a rotation around two dihedral angles, ~90° around the C1’– C2’ bond and ~180° around the N10 – C1’ bond. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)


position [36] (Fig. 5C). Steady-state and pre-steady-state kinetic experiments performed using the SidA M101A variant show that the mutation slows down events occurring after the flavin reduction step. Furthermore, the crystal structure of M101A in complex with NADP<sup>+</sup> displays the FAD in the “out” position, in contrast to what is observed for the wild-type SidA. It is proposed that M101 is involved in regulation of flavin motion and mutation to Ala reduced the flavin motion and makes NADP<sup>+</sup> release the rate limiting step [46].

The exact mechanism of how mobile flavins play a role in the mechanisms of NMO catalyzed reactions remains unclear. However, it is becoming evident that flavin motion is not only present in class A monooxygenases. In addition, new information from various enzyme complexes and conformational changes could be exploited in NMOs since these enzymes are potential drug targets. Applications of NMOs as potential drug targets will be discussed in Section 2.3.

## 2.2. Formation and stabilization of the Fl<sub>4a</sub>-OOH

The activation of molecular oxygen has been extensively studied and significant progress has been made over the years [47]. In this section, important advancements in our understanding of Fl<sub>4a</sub>-OOH formation and stabilization in FMOs will be discussed. The activation of oxygen involves a single electron transfer from the reduced flavin forming a flavin semiquinone and superoxide anion radical pair that recombines to constitute a Fl<sub>4a</sub>-OO<sup>·</sup>, which protonates forming Fl<sub>4a</sub>-OOH [12,47].

For BVMO reactions, Fl<sub>4a</sub>-OO<sup>·</sup> is required for catalysis and it is believed that the presence of a conserved arginine residue in the active site provides an environment that stabilizes the unprotonated form of the intermediate [48]. FMOs that catalyze hydroxylation reactions require Fl<sub>4a</sub>-OOH and the mechanism of protonation depends on the enzyme class. The active site of NMO and flavin-containing



**Fig. 4.** Representation of the binding conformation of NADP<sup>+</sup> in class B monooxygenases. A) Hydride transfer of the proR-position of the NADPH to the flavin-N5 atom supported by extensive biochemical studies. B) NADP<sup>+</sup> binding in class B monooxygenases is not optimal for hydride transfer. The coordinates for SidA (PDB ID: 4B63) were used in this figure. C) Predicted hydrogen bonding patterns for the complex with NADP<sup>+</sup> and F1<sub>ox</sub> or F1<sub>4a</sub>-OOH.

monooxygenases lack residues adjacent to the flavin-C4a-atom that can facilitate protonation of the F1<sub>4a</sub>-OO<sup>·</sup>. However, the 2'-OH group of the NADP<sup>+</sup> ribose is ~5 Å from the C4a-position. Solvent kinetic isotope effects (SKIEs) and density functional theory (DFT) have shown that the 2'-OH is involved in rapid proton transfer (Fig. 6) [15]. Structural studies showed that there is a water mediated hydrogen bond network that links the 2'-OH with bulk solvent, facilitating this process. Rapid reaction kinetics and pH studies have shown that in the two component monooxygenase *p*-hydroxyphenylacetate-3-hydroxylase (HPA) (class D), protonation of the F1<sub>4a</sub>-OO<sup>·</sup> is catalyzed by a His residue (His396 in HPA from *Acinetobacter baumannii*) that is ~4.6 Å from the flavin-C4a position [16]. SKIEs suggest that proton transfer is not rate limiting in the formation of the F1<sub>4a</sub>-OOH. DFT studies on pyranose oxidase, which also stabilizes the F1<sub>4a</sub>-OOH, suggest that protonation of the superoxide anion before covalent attachment to the flavin C4a-position might occur to neutralize the negative charge [17]. It might also be possible that protonation of superoxide anions by NADP<sup>+</sup>-2'-OH occurs before formation of F1<sub>4a</sub>-OOH. Regardless of the timing of the protonation step, members of class B FMOs take advantage of the presence of NADP<sup>+</sup> in the active site to form F1<sub>4a</sub>-OOH, while class D FMOs recruit active site residues to act as proton donors. Similar studies have not been performed with the class A monooxygenases, but it is reasonable to assume that protonation will occur from conserved active site residues.

After formation, F1<sub>4a</sub>-OOH stabilization varies depending on the enzyme class. Class B monooxygenases rely on interactions with NADP<sup>+</sup> to provide the high F1<sub>4a</sub>-OOH stability observed in these enzymes. As briefly mentioned in the previous sections, hydrogen bonding between the nicotinamide carbonyl oxygen and the F1-N5-H atom is essential to prevent the expulsion of hydrogen peroxide from the F1<sub>4a</sub>-OOH. The important stabilizing role of this interaction is supported by computational analyses and was probed using NADP<sup>+</sup> analogs [18,33,41,49]. Additional stabilization is obtained from hydrogen bonding with the O-atom at the 2'-ribose (Fig. 6). Two-component monooxygenases utilize a similar approach, where hydrogen bonding with the F1-N5-H and the F1<sub>4a</sub>-OOH distal oxygen occur; however, this happens with conserved active site residues (Fig. 6) [50].

### 2.3. Hydroxylation mechanism


A combination of experimental and computational methods has been used to investigate the hydroxylation mechanism and substrate selectively in FMOs at the molecular level. F1<sub>4a</sub>-OOH is generally considered an “OH<sup>+</sup>” donor, functioning as an electrophile to be attacked by a nucleophile (Fig. 7). Experimental data was analyzed in favor of the nucleophilic mechanism (Fig. 7) from studies of C8-modified FAD with PHBH. It was shown that electron withdrawing groups accelerated the rate constant for hydroxylation and it was concluded that electrophilic aromatic substitution best explained the data [52]. Computational

studies have been performed in support of this mechanism and, in general, the nucleophilic mechanism has been accepted as the mechanism of action of FMOs [11,53,54].

The availability of more structures, including complexes with substrates, as well as advances in computational biomolecule modeling allowed further evaluation of the hydroxylation mechanism of FMOs. QM/MM (quantum mechanics/molecular mechanics) and DFT studies suggested a homolytic cleavage of the O-OH bond and transfer of a hydroxyl radical as an alternative mechanism for PHBH [55]. The calculations highlighted the stabilization of the reacting OH group of the F1<sub>4a</sub>-OOH intermediate by Pro293. In one study, the backbone of Pro293 (numbering in PHBH from *Pseudomonas fluorescens*) was proposed to interact with the reacting OH through hydrogen bonding, which lowered the energy of the transition state [56]. This is in agreement with the observation that the PHBH P293S mutant had a lower rate of hydroxylation [57]. Another study pinpointed this interaction with the Pro293 amide oxygen, although a nucleophilic mechanism was applied in this calculation [53].

Biochemical evidence in support of a homolytic bond cleavage has been available since the late 80's from reports of the detection of hydroxyl radicals generated by pulse radiolysis [58,59]. Further support of this hydroxyl radical mechanism in NMOs has come from DFT studies with SidA. SidA is one of the few FMOs for which structures with several ligands are available. In addition to the structures with NADP<sup>+</sup> and ornithine, the structure with lysine is also available. Lysine is only one carbon longer than ornithine; however, with this amino acid, turnover results in ~90% H<sub>2</sub>O<sub>2</sub> release and only ~10% hydroxylated-lysine. In contrast, in the presence of ornithine, the hydroxylation is ~95% efficient. DFT studies with SidA in complex with ornithine or lysine were consistent with homolytic cleavage of the F1<sub>4a</sub>-OOH and hydroxylation by hydroxyl radical transfer. The studies also suggested that ornithine binds with the N5-atom in the deprotonated form, which was later supported by pH studies [60]. The hydroxyl radical mechanism provides a logical explanation for the substrate selectivity of SidA. It shows that due to the extended binding position of lysine in the active site, the hydrogen bonding interactions in the transition state are not optimized for lysine hydroxylation (Fig. 8). This results in an increase in the activation energy of 8 kcal/mol (Fig. 8) [18]. The fact that substrate selectivity in SidA can be explained by transition state stabilization of the hydroxyl radical provides further support for this mechanism.

A more recent study also used DFT simulations to investigate the mechanism of substrate hydroxylation in the fungal enzyme TropB, a class A flavin-dependent hydroxylase [61]. It was established that in the reaction catalyzed by TropB, a hydroxyl radical-coupled electron transfer mechanism (HRC-ET) is favored by ~ 7 kcal/mol compared to the electrophilic aromatic substitution. TropB, as well as PHBH, is involved in the hydroxylation of aromatic compounds and these enzymes have similar structures. These computational studies suggest that



**Fig. 5.** Conformational changes in the SidA active site. (A) Ligand free form (PDB ID 6X0H) with the oxidized flavin stabilized in the “out” conformation (yellow) by Tyr324. Side chains around the flavin are shown in light blue. (B) NADPH-reduced SidA (PDB ID 6X0J) in complex with NADP<sup>+</sup> (orange) and ornithine (green). The reduced “in” FAD is colored in gray and the side chains around the flavin are shown in light pink. (C) The overlay of panes A and B, NADPH, and L-Ornithine were omitted for clarity. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

the mechanism of hydroxylation by FMOs requires re-evaluation. Computational data is now available that support a hydroxyl radical mechanism for class A and B monooxygenases and might represent a general mechanism of action for FMOs.

### 3. Novel catalysis and applications of FMOs

Bacterial genome sequencing projects and metagenomic studies have

greatly accelerated the identification of biosynthetic gene clusters of natural products with significant health benefits, such as anti-cancer, antibiotic, and anti-inflammatory activities, among others [62–64]. Some of these natural products have unique functional groups that are important for the structure or chemical properties of these compounds and many novel FMOs are being identified in these biological pathways.

As our knowledge of FMO chemistry and catalysis expands, new applications for FMOs become possible. FMO activity is applied in nature to initiate the catabolism of xenobiotics [65]. This activity has also been recruited by bacteria for the degradation or inactivation of clinically used antibiotics. FMO activity has also been shown to be essential for the virulence of several human pathogens, which has led to several drug discovery programs targeting FMOs. Here, we focus on selected cases of novel FMOs involved in natural product biosynthesis and FMOs identified in antibiotic resistant mechanisms and as potential drug targets.

#### 3.1. Double hydroxylation reactions by novel NMOs

SidA and PvdA have been intensively studied due to their essential function in siderophore biosynthesis. These NMOs catalyze the single hydroxylation of amine-containing substrates, such as lysine and ornithine, to hydroxylamine products. However, several recently identified NMOs are capable of catalyzing consecutive oxidations of amines to generate oximes or nitrones (Fig. 9). CrmH from *Streptomyces caeruleus* was the first NMO found to generate oximes [10]. The catalytic mechanism of CrmH is believed to involve the double hydroxylation of the substrate, caerulomycin N, to form dihydroxylamine, which then dehydrates and tautomerizes to form the oxime-containing caerulomycin A. Caerulomycin A has a unique 2,2'-bipyridine skeleton and shows attractive potential bioactivities such as antifungal, antiamoebic, and antitumor [62] properties. In *Streptomyces* species, PcxL and Hpx catalyze similar oxidation reactions of 2-aminoethylphosphonate (2AEPn) and (R)-1H2AEPn, respectively, to corresponding aldoximes, which are further oxidized to nitrosylated phosphonic acid products through multiple steps [66]. Oxime-containing small molecules are reported to have interesting biological properties such as antibacterial, antifungal, insecticidal, antitumor, immunosuppressive, and acetylcholinesterase reactivation activities [66].


OxD from *Penicillium oxalicum* F30 generates nitrone alkaloid roquefortine L [67]. In the proposed mechanism, oxidation of roquefortine C to the hydroxylamine product is further oxidized to the nitrone in roquefortine L. Roquefortine is an example of a biosynthetically related prenylated indole alkaloid. Potent antibacterial, anticancer, antiparasitic, and insecticidal activities [63,64] have been reported for this class of compounds.

The NMOs, FzmM and its analog CreE convert aspartic acid to nitrosuccinate via double hydroxylation. Nitrosuccinate is subsequently converted to nitrous acid and fumarate by FzmL or CreD [9,68,69]. Nitrous acid is the N-donor for the formation of the N-N bond in the biosynthetic pathways of fosfazinomycin and cremeomycin. The structures of these enzymes are currently unavailable, and their amino acid sequences show low conservation to other FMOs. FzmM and CreE are distantly related to PcxL and HpxL, which were previously discussed.


Detailed mechanistic and structural studies of these interesting newly identified NMOs have the promise of shedding new light onto FMO chemistry. Determining the kinetic mechanism and solving the three-dimensional structure of these enzymes will allow the elucidation of the chemical mechanisms that will be important for engineering novel molecular scaffolds with improved biological activities.

#### 3.2. Role of FMOs in antibiotic resistance


Antibiotic resistance poses increasing risks to patients by limiting the function of currently used antibiotics for the treatment of a wide range of infections, including life-threatening pneumonia [70]. Due to the broad



**Fig. 6.** Protonation and stabilization mechanism in FMOs. A) Protonation mechanism in class B monooxygenases. Protonation of the distal oxygen of  $\text{Fl}_{4a}\text{-OO}^-$  is – facilitated by the ribose 2'-OH of  $\text{NADP}^+$  (right) or protonation might occur directly to the superoxide anion (left). In two component monooxygenases, the proton donor is a His residue. B) Hydrogen bonding interactions involved in  $\text{Fl}_{4a}\text{-OOH}$  stabilization in class B monooxygenases or (C) two component monooxygenases (Ser171 and His396 in HPA) [51].



**Fig. 7.** Proposed hydroxylation mechanism of substrates in FMOs.




**Fig. 8.** Hydrogen bonding interaction in the transition state for the hydroxylation of (A) ornithine (shown in cyan), and (B) lysine (shown in purple) in the SidA active site obtained by DFT calculations [18]. NADPH is shown in orange and the Asn323 side chain is shown in gray. The transition state for hydroxyl radical transfer with ornithine is stabilized by a strong hydrogen bond with the  $\text{NADP}^+$ -2'OH. The transition state for lysine is instead stabilized by a weak hydrogen bond with the  $\text{NADP}^+$ -3'OH. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

substrate scope of FMOs, the active sites of microbial FMOs can accommodate antibiotics for oxidation reactions, leading to deactivation and, ultimately, resistance to certain antibiotics. Several microbial FMOs have been discovered and characterized for their functions in resistance to tetracyclines, rifampicin, sulfonamides, and imipenem antibiotics.

The enzyme tetracycline destructase, TetX, was the first FMO

discovered that conferred antibiotic resistance against multiple tetracyclines, including tigecycline. Initially discovered from *Bacteroides*, this class A FMO was found to hydroxylate the C11a of tigecycline to produce 11a-hydroxytigecycline (Fig. 10A). The crystal structure of tetracycline-bound TetX revealed the short distance between tetracycline C11a and the flavin C4a (~5.9 Å) [71]. A strongly hydrophobic pocket was assigned as the putative oxygen binding site. Together with a



**Fig. 9.** Reactions catalyzed by (A) CrmH, (B) HpxL and PcxL, (C) OxaD, and (D) FzmM and CreE.

crystal structure of TetX2, a TetX ortholog, it was determined that TetX is a class A FMO [72]. Wild type TetX (Mab TetX) from *Mycobacterium abscessus* was recently found to also contribute to the high tetracycline resistance [73]. Moreover, genes encoding TetX3 and TetX4 in numerous Enterobacteriaceae and *Acinetobacter* have been isolated from animals and humans, which could cause compromised infection treatment by tetracyclines [74].

Rifampicin monooxygenase (RIFMO), another class A FMO, is encoded by the rox gene in *Nocardia farcinica* and was initially suggested to convert the frontline anti-tuberculosis drug rifampicin (RIF) to 2'-N-hydroxy-4-oxo-rifampicin (RIF-2'-N-OH) [75]. However, evidence of RIF-2'-N-OH existence was only supported by mass spectroscopy. Closer scrutiny of the crystal structure of the RIFMO-RIF complex by NMR analysis found that the oxidation product was RIF-OH (Fig. 10B), formed through hydroxylation of C2 followed by hydrolytic cleavage of the ansa-bridge [76,77].

A novel Baeyer-Villiger monooxygenase (Ar-BVMO, class B FMO), isolated from *Acinetobacter radioresistens*, was found to have the activity of oxidizing the carbonyl moiety of the  $\beta$ -lactam ring (Fig. 11A). Asymmetric oxygen insertion yielded two products [78]. The crystal structure of SaFMO, a BVMO from methicillin- and vancomycin-resistant *Staphylococcus aureus* strain MU50, has been reported [79]. Although a molecular docking study revealed the accessibility of the SaFMO active site to vancomycin and/or methicillin, the function and substrate specificity remains to be explored.

The biosynthesis of 1,2,4-trihydroxybenzene involves the sequential action of two monooxygenase components, SadA and SadB. The reductase component that provides the reduced FMN is known as SadC (Fig. 11B). SadA converts sulfamethoxazole to 4-aminophenol, which is

subsequently converted by SadB to 1,2,4-trihydroxybenzene [80]. These products do not show antibiotic activity, so the presence of SadA results in a reduction of the bacteriostatic effect of sulfonamides. A different two component FMO system, encoded by the monooxygenase gene sulX and the reductase gene sulR (Fig. 11C), was found to catalyze similar oxidation steps to SadA/SadC [81]. In this system, the sulfonamide monooxygenase was a very close analog of SadA (95.5% identity) [81]. These monooxygenases belong to the class C FMOs.

### 3.3. Drug discovery program targeting FMOs


Only a few FMOs have been investigated as potential drug targets. Among these, kynurenine 3-monooxygenase (KMO), a class A FMO, is the most studied due to its role in tryptophan catabolism [82]. Catalyzing the hydroxylation of L-kynurenine, KMO generates the neurotoxin 3-hydroxykynurenine and causes neurodegeneration and/or neuroinflammation [82]. Targeting KMO is an attractive treatment approach for illnesses such as Alzheimer's disease [83] and acute pancreatitis [84,85]. KMO inhibitor development has been accomplished through fluorescence-based high throughput screening (HTS) and rational drug design (Fig. 12A) [86,87]. However, structural analogs of L-kynurenine should be studied with caution to inhibit KMO since they uncouple the oxidation process and generate high levels of cytotoxic hydrogen peroxide [87,88].

Inhibition of FMOs involved in the cholesterol synthesis pathway can also be beneficial. Human squalene epoxidase (SQLE) inhibition causes accumulation of toxic squalene and presents itself as a novel target for neuroendocrine cancers [89]. NB-598 was found to specifically inhibit SQLE ( $IC_{50} = 63$  nM) [90] and suppress de novo cholesterol biosynthesis in small cell lung cancer cells ( $IC_{50} = 76$  nM) [91]. A high resolution crystal structure of human SQLE has also been reported revealing the inhibitor binding site [90]. The key residue of human SQLE, Tyr195, was found to form hydrogen bonds with the Gln168 side chain in the presence and absence of hydrophilic substrate. However, upon binding with inhibitors, Tyr195 changes its residue orientation, which favors its interaction with the amine groups of the inhibitors. This binding mode could inspire design of next-generation inhibitors. In the cholesterol synthesis pathway, another potential FMO target studied was squalene synthase (SQS), which has been investigated as an antifungal target against *Aspergillus flavus* [92]. Celastrol was found to be an inhibitor of ASQS, with an  $IC_{50}$  of 0.83  $\mu$ M.

Our group developed a colorimetric high-throughput screening platform and identified celastrol (Fig. 12B) as an inhibitor of *A. fumigatus* growth ( $MIC = 2$   $\mu$ M) [93]. The screening was performed against SidA and its higher  $IC_{50}$  value ( $IC_{50} = 11$   $\mu$ M) suggested that it might be a multi-target inhibitor [92]. Similar drug discovery strategies might apply to other N-hydroxylating monooxygenases involved in siderophore synthesis, such as PvdA and NbtG [44,94]. More recently, the "out" conformation adopted by the FAD in the active site of SidA has been exploited as a potential new binding pocket for drug discovery. A fragment-mapping approach was used for SidA to identify new ligand binding spots [14].

Since TetX has been proven to be the deactivator of tetracycline drugs, administration of TetX inhibitor in combination with tetracyclines should restore the activity of tetracyclines [95]. Anhydrotetracycline, a biosynthetic precursor of tetracycline, has been shown to prevent tetracycline degradation by TetX, thus, proving the concept of such a co-administration strategy [95,96]. In fact, it was established that anhydrotetracycline binds to the active site of TetX and locks FAD in the unproductive "out" conformation. This mechanism exists in a relevant clinical application of flavin mobility in monooxygenases.

A more recently discovered BVMO, MymA, is involved in mycolic acid synthesis and serves as a target of isoniazid [97]. A thioalkylbenzoxazole compound, discovered by GSK scientists through screening of intracellular *Mycobacterium tuberculosis* growth was found to have anti-tuberculosis activity. Since S-oxidation is known to activate



**Fig. 10.** (A) TetX-catalyzed hydroxylation of tigecycline. (B) Proposed mechanism of RIFMO-catalyzed hydroxylation of rifampicin.

anti-tuberculosis drugs, this compound was tested against a panel of *ethA* and *mymA* mutant strains. The increased resistance of *mymA* mutants suggested that this compound was bioactivated by MymA, presumably to the corresponding sulfoxide and sulfone (Fig. 13) [98]. However, the catalytic mechanism remains to be elucidated.

#### 3.4. FMO in synthesis of drug candidates

EpnF is a flavin-dependent enzyme from *Streptomyces hygroscopicus* that was found to catalyze a key step in the biosynthesis of epoxyketone pharmacophore. The reaction is characterized as a cascade of decarboxylation-dehydrogenation-monoxygenation reactions (Fig. 14). TMC-86 A is a natural  $\alpha,\beta$ -epoxyketone that covalently modifies the essential threonine residue of the proteasome  $\beta$ -subunit.


It is well established that epoxyketone proteasome inhibitors constitute a class of therapeutic agents for cancer treatment [99]. In fact, carfilzomib, a synthetic tetrapeptide epoxyketone proteasome inhibitor, was approved for multiple myeloma treatment. Epoxyketones have also shown antiparasitic activities [100]. In the context of natural product-based drug discovery, synthetic substrates have been incubated with EpnF to afford analogs of TMC-86A when searching for candidates with improved activity [101].

#### 4. Conclusions


The flavoenzymology field has advanced our understanding of the reactions catalyzed by flavoenzymes in vast detail. The combination of biochemical, structural, and computational tools allowed the elucidation of the mechanisms of C-H and O-H bond cleavage by oxidases [102,103]. The study of FMOs has also significantly benefited from multidisciplinary approaches to probe the various steps in this multi-substrate/redox reaction. Trapping and characterization of intermediates in *crystallo* have

been particularly important. For many years, the characterization of the “waving” flavin in class A FMOs provided a logical explanation of the kinetic mechanism, where substrate binding is required to trigger flavin motion for reaction with NADPH. Similarly, the structure of FMOs in complex with NADP<sup>+</sup> highlighted potential interactions that provided clues to the mechanism of Fl<sub>4a</sub>-OOH stabilization in class B FMOs. Further biochemical studies, in particular stopped-flow spectroscopy combined with kinetic isotope effects, were used to study the various steps in the oxidative half-reactions, particularly the protonation of Fl<sub>4a</sub>-OO<sup>·</sup> and H<sub>2</sub>O<sub>2</sub> or H<sub>2</sub>O elimination. The availability of three-dimensional structures in complex with substrates and in different redox states provided valuable information that has been used in computational studies to probe the hydroxylation mechanism.

Altogether, the field of FMOs was believed to be represented by class A monooxygenases utilizing the cautious mechanism with the “waving” flavin allowing the reduction to occur in a different site than hydroxylation. On the other hand, class B monooxygenases were thought to follow the bold mechanism, performing the reduction and oxidation reaction in the same active site, with NADP(H) reducing the flavin and stabilizing the Fl<sub>4a</sub>-OOH. An updated version of the NMOs’ mechanism with emphasis on the data from SidA is shown in Fig. 15. Flavin motion in NMOs is proposed to be modulated by the Tyr-loop rearrangements. In the “out” position, the flavin isoalloxazine ring can be seen stacking with a conserved Tyr (Fig. 15A). This type of interaction was previously characterized in ferredoxin-NADP<sup>+</sup> oxidases. In this flavoenzyme, a C-terminus conserved tyrosine residue stacks with the flavin isoalloxazine system. The motion of the phenol ring of this tyrosine residue was proposed to be responsible for the decrease in the binding energy of the charge transfer complex between NADPH-Fl<sub>ox</sub> or NADP<sup>+</sup>-Fl<sub>red</sub>, that otherwise would form a tight dead-end complex [104–106]. It is possible that in NMOs, similar to what has been described for class A FMOs, reaction with NADPH occurs with the flavin in the “out” position



**Fig. 11.** (A) Ar-BVMO-catalyzed oxidation of imipenem. (B) Proposed mechanism of sulfamethoxazole degradation catalyzed by SadA/SadC and SadB/SadC. (C) Proposed mechanism of sulfamethazine degradation catalyzed by a two-component FMO system encoded by sulX/sulR.



**Fig. 13.** Activation of anti-tuberculosis agent by FMO MymA.

(Fig. 15B). In this context, the conserved tyrosine residue would be responsible for modulating the interaction between the nicotinamide and the isoalloxazine ring to prevent the formation of a tight stable complex. It is also possible that the tyrosine residue is involved in the positioning of the nicotinamide for proR hydride transfer in the orientation required for stabilization of the Fl<sub>4a</sub>-OOH (Fig. 15C). Solving the structure of the complex between NADPH and class B FMOs remains a key piece of the puzzle that is still missing. Molecular dynamic studies that can identify the conformational motions involved in flavin dynamics and NADP(H) entrance and exit of the active site should be a major focus in the FMO field. Although, a Tyr-loop is not generally

**Fig. 12.** (A) Structures of screen hits for KMO. (B) Structure of SidA inhibitor celastrol.





Fig. 14. Proposed catalytic cascade of EpnF.



**Fig. 15.** Proposed mechanism for NMOs from biochemical, structural, and computational studies on SidA. NADP<sup>+</sup> and ornithine are shown in orange and cyan, respectively. (A) SidA ligand free form (PDB ID 6X0H) with the oxidized flavin. In this complex, the flavin is in the "out" position and interacts with Tyr-loop. (B) Unknown molecular details on the complex formed between the oxidized flavin and NADPH (C). The NADPH-reduced SidA (PDB ID 4B65) in complex with NADP<sup>+</sup>. (D) Fl<sub>4a</sub>-OOH stabilization by hydrogen bonding with NADP<sup>+</sup>. Protonation of the distal oxygen by the 2'OH is not shown. (E) Complex between bond in Fl<sub>4a</sub>-OOH and ornithine. (F) Hydrogen bonding interaction in the transition state for the hydroxylation of ornithine through homolytic cleavage of the O-OH. (G) Proposed complex of Fl<sub>4a</sub>-OH, NADP<sup>+</sup>, and hydroxyornithine. After H<sub>2</sub>O elimination and hydroxyornithine release, the complex of oxidized enzyme with NADP<sup>+</sup> is generated (PDB ID 6X0I) (H) and release of NADP<sup>+</sup> completes the catalytic cycle. The predicted conformation changes of the flavin to the "out" position, to facilitate NADP<sup>+</sup> release (H-A) and to the "in" position upon NADPH binding/reduction (A-C) are also shown. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)

conserved in all members of class B monooxygenase, flavin motion could also take place in BVMO and flavin-containing monooxygenases by interactions with yet unidentified residues.

Stabilization of the  $\text{Fl}_{4a}$ -OOH is dependent on hydrogen bonding with  $\text{NADP}^+$ . Ribose hydroxyl groups are involved in protonation in addition to stabilization (Fig. 15D). The precise timing of the protonation is not clearly understood as protonation of the superoxide has been proposed. The interaction is also conserved in two component FMOs but occurs with active site residues as  $\text{NADP}^+$  is not present. The mechanism of hydroxylation of substrates in FMOs has been probed by computational studies. Homolytic cleavage and hydroxyl radical transfer have reemerged as possible mechanisms for class A and B FMOs (Fig. 15E). Further support for these mechanisms will come from more computational studies as well as from mechanistic studies with alternative substrates and enzymes variants.

Ultimately, the biochemical and structural characterization of new FMOs involved in the functionalization of N-groups will provide the basis for the engineering of new pharmacological agents. Similarly, inactivation of FMOs can be targeted for the identification of small molecules for the treatment of microbial infections and other diseases. The unique conformational states that FMOs undergo during catalysis can be exploited in the development of new and selective inhibitors against these enzymes.

## Funding

This work was supported by National Science Foundation grant CHE 2003658.

## Notes

The authors declare no competing financial interest.

## References

- [1] P. Chaiyen, M.W. Fraaije, A. Mattevi, The enigmatic reaction of flavins with oxygen., *Trends Biochem. Sci.* 37 (2012) 373–380.
- [2] W.J. van Berkel, N.M. Kamerbeek, M.W. Fraaije, Flavoprotein monooxygenases, a diverse class of oxidative biocatalysts, *J. Biotechnol.* 124 (2006) 670–689.
- [3] M.L. Mascotti, M. Juri Ayub, N. Furnham, J.M. Thornton, R.A. Laskowski, Chopping and changing: the evolution of the flavin-dependent monooxygenases, *J. Mol. Biol.* 428 (2016) 3131–3146.
- [4] M.M. Huijbers, S. Montersino, A.H. Westphal, D. Tischler, W.J. van Berkel, Flavin dependent monooxygenases, *Arch. Biochem. Biophys.* 544 (2014) 2–17.
- [5] T. Heine, A. Scholtissek, S. Hofmann, R. Koch, D. Tischler, Accessing enantiopure epoxides and sulfoxides: related flavin-dependent monooxygenases provide reversed enantioselectivity, *ChemCatChem* 12 (2020) 199–209.
- [6] M. Gibson, M. Nur-e-alam, F. Lipata, M.A. Oliveira, J. Rohr, Characterization of kinetics and products of the Baeyer-Villiger oxygenase MtmOIV, the key enzyme of the biosynthetic pathway toward the natural product anticancer drug mithramycin from *Streptomyces argillaceus*, *J. Am. Chem. Soc.* 127 (2005) 17594–17595.
- [7] S.S. Gao, A. Duan, W. Xu, P. Yu, L. Hang, K.N. Houk, Y. Tang, Phenalenone polyketide cyclization catalyzed by fungal polyketide synthase and flavin-dependent monooxygenase, *J. Am. Chem. Soc.* 138 (2016) 4249–4259.
- [8] R. Teufel, Flavin-catalyzed redox tailoring reactions in natural product biosynthesis, *Arch. Biochem. Biophys.* 632 (2017) 20–27.
- [9] Z. Huang, K.A. Wang, W.A. van der Donk, New insights into the biosynthesis of fosfazinomycin, *Chem. Sci.* 7 (2016) 5219–5223.
- [10] Y. Zhu, Q. Zhang, S. Li, Q. Lin, P. Fu, G. Zhang, H. Zhang, R. Shi, W. Zhu, C. Zhang, Insights into caerulomycin A biosynthesis: a two-component monooxygenase CrmH-catalyzed oxime formation, *J. Am. Chem. Soc.* 135 (2013) 18750–18753.
- [11] B.A. Palfey, C.A. McDonald, Control of catalysis in flavin-dependent monooxygenases, *Arch. Biochem. Biophys.* 493 (2010) 26–36.
- [12] V. Massey, Activation of molecular oxygen by flavins and flavoproteins, *J. Biol. Chem.* 269 (1994) 22459–22462.
- [13] J.W. Setser, J.R. Heemstra Jr., C.T. Walsh, C.L. Drennan, Crystallographic evidence of drastic conformational changes in the active site of a flavin-dependent N-hydroxylase, *Biochemistry* 53 (2014) 6063–6077.
- [14] A.C. Campbell, K.M. Stiers, J.S. Martin Del Campo, R. Mehra-Chaudhary, P. Sobrado, J.J. Tanner, Trapping conformational states of a flavin-dependent N-monooxygenase in crystallo reveals protein and flavin dynamics, *J. Biol. Chem.* 295 (2020) 13239–13249.
- [15] R. Robinson, S. Badieyan, P. Sobrado, C4a-hydroperoxyflavin formation in N-hydroxylating flavin monooxygenases is mediated by the 2'-OH of the nicotinamide ribose of NADP(+), *Biochemistry* 52 (2013) 9089–9091.
- [16] P. Chenprakhon, D. Trisrirat, K. Thotsaporn, J. Sucharitakul, P. Chaiyen, Control of C4a-hydroperoxyflavin protonation in the oxygenase component of p-hydroxyphenylacetate-3-hydroxylase, *Biochemistry* 53 (2014) 4084–4086.
- [17] T. Wongnate, P. Surawatanawong, S. Visitsatthawong, J. Sucharitakul, N. S. Scruton, P. Chaiyen, Proton-coupled electron transfer and adduct configuration are important for C4a-hydroperoxyflavin formation and stabilization in a flavoenzyme, *J. Am. Chem. Soc.* 136 (2014) 241–253.
- [18] S. Badieyan, R.D. Bach, P. Sobrado, Mechanism of N-hydroxylation catalyzed by flavin-dependent monooxygenases, *J. Org. Chem.* 80 (2015) 2139–2147.
- [19] M.W. Fraaije, A. Mattevi, Flavoenzymes: diverse catalysts with recurrent features, *Trends Biochem. Sci.* 25 (2000) 126–132.
- [20] C.T. Walsh, T.A. Wencewicz, Flavoenzymes: versatile catalysts in biosynthetic pathways, *Nat. Prod. Rep.* 30 (2013) 175–200.
- [21] D. Leys, N.S. Scruton, Sweating the assets of flavin cofactors: new insight of chemical versatility from knowledge of structure and mechanism, *Curr. Opin. Struct. Biol.* 41 (2016) 19–26.
- [22] V. Piano, B.A. Palfey, A. Mattevi, Flavins as covalent catalysts: new mechanisms emerge, *Trends Biochem. Sci.* 42 (2017) 457–469.
- [23] L. De Colibus, A. Mattevi, New frontiers in structural flavoenzymology, *Curr. Opin. Struct. Biol.* 16 (2006) 722–728.
- [24] D.L. Gatti, B.A. Palfey, M.S. Lah, B. Entsch, V. Massey, D.P. Ballou, M.L. Ludwig, The mobile flavin of 4-OH benzoate hydroxylase, *Science* 266 (1994) 110–114.
- [25] P.A.W. Van Den Berg, K. Grever, A. Van Hoek, W.J.H. Van Berkel, A.J.W. G. Visser, Time-resolved fluorescence analysis of the mobile flavin cofactor in p-hydroxybenzoate hydroxylase, *J. Chem. Sci.* 119 (2007) 123–133.
- [26] W.J. van Berkel, M.H. Eppink, H.A. Schreuder, Crystal structure of p-hydroxybenzoate hydroxylase reconstituted with the modified FAD present in alcohol oxidase from methylotrophic yeasts: evidence for an arabinoflavin, *Protein Sci.* 3 (1994) 2245–2253.
- [27] K. Crozier-Reabe, G.R. Moran, Form follows function: structural and catalytic variation in the class I flavoprotein monooxygenases, *Int. J. Mol. Sci.* 13 (2012) 15601–15639.
- [28] B. Entsch, L.J. Cole, D.P. Ballou, Protein dynamics and electrostatics in the function of p-hydroxybenzoate hydroxylase, *Arch. Biochem. Biophys.* 433 (2005) 297–311.
- [29] M. Husain, V. Massey, Kinetic studies on the reaction of p-hydroxybenzoate hydroxylase. Agreement of steady state and rapid reaction data, *J. Biol. Chem.* 254 (1979) 6657–6666.
- [30] H.A. Schreuder, P.A. Prick, R.K. Wierenga, G. Vriend, K.S. Wilson, W.G. Hol, J. Drenth, Crystal structure of the p-hydroxybenzoate hydroxylase-substrate complex refined at 1.9 Å resolution. Analysis of the enzyme-substrate and enzyme-product complexes, *J. Mol. Biol.* 208 (1989) 679–696.
- [31] F.J. van der Bolt, J. Vervoort, W.J. van Berkel, Flavin motion in p-hydroxybenzoate hydroxylase. Substrate and effector specificity of the Tyr22->Ala mutant, *Eur. J. Biochem.* 237 (1996) 592–600.
- [32] N.A. Baker, D. Sept, S. Joseph, M.J. Holst, J.A. McCammon, Electrostatics of nanosystems: application to microtubules and the ribosome, *Proc. Natl. Acad. Sci. U. S. A.* 98 (2001) 10037–10041.
- [33] C. Shirey, S. Badieyan, P. Sobrado, Role of Ser-257 in the sliding mechanism of NADPH in the reaction catalyzed by the *Aspergillus fumigatus* flavin-dependent ornithine N5-monooxygenase SidA, *J. Biol. Chem.* 288 (2013) 32440–32448.
- [34] E. Malito, A. Alfieri, M.W. Fraaije, A. Mattevi, Crystal structure of a Baeyer-Villiger monooxygenase, *Proc. Natl. Acad. Sci. U. S. A.* 101 (2004) 13157–13162.
- [35] S. Eswaramoorthy, J.B. Bonanno, S.K. Burley, S. Swaminathan, Mechanism of action of a flavin-containing monooxygenase, *Proc. Natl. Acad. Sci. U. S. A.* 103 (2006) 9832–9837.
- [36] S. Franceschini, M. Fedkenheuer, N.J. Vogelaar, H.H. Robinson, P. Sobrado, A. Mattevi, Structural insight into the mechanism of oxygen activation and substrate selectivity of flavin-dependent N-hydroxylating monooxygenases, *Biochemistry* 51 (2012) 7043–7045.
- [37] E. Romero, R. Robinson, P. Sobrado, Monitoring the reductive and oxidative half-reactions of a flavin-dependent monooxygenase using stopped-flow spectrophotometry, *JoVE* 61 (2012) 1–6, e3803.
- [38] N.B. Beaty, D.P. Ballou, The reductive half-reaction of liver microsomal FAD-containing monooxygenase, *J. Biol. Chem.* 256 (1981) 4611–4618.
- [39] R.M. Robinson, P.J. Rodriguez, P. Sobrado, Mechanistic studies on the flavin-dependent N(6)-lysine monooxygenase MbsG reveal an unusual control for catalysis, *Arch. Biochem. Biophys.* 550–551 (2014) 58–66.
- [40] A. Alfieri, E. Malito, R. Orru, M.W. Fraaije, A. Mattevi, Revealing the moonlighting role of NADP in the structure of a flavin-containing monooxygenase, *Proc. Natl. Acad. Sci. U.S.A.* 105 (2008) 6572–6577.
- [41] R. Orru, H.M. Dudek, C. Martinoli, Torres Pazmino, D. E, A. Royant, M. Weik, M. W. Fraaije, A. Mattevi, Snapshots of enzymatic baeyer-villiger catalysis: oxygen activation and intermediate stabilization, *J. Biol. Chem.* (2011).
- [42] M.J. Furst, F. Fiorentini, M.W. Fraaije, Beyond active site residues: overall structural dynamics control catalysis in flavin-containing and heme-containing monooxygenases, *Curr. Opin. Struct. Biol.* 59 (2019) 29–37.
- [43] I.A. Mirza, B.J. Yachnin, S. Wang, S. Grosse, H. Bergeron, A. Imura, H. Iwaki, Y. Hasegawa, P.C. Lau, A.M. Berghuis, Crystal structures of cyclohexanone monooxygenase reveal complex domain movements and a sliding cofactor, *J. Am. Chem. Soc.* 131 (2009) 8848–8854.
- [44] C. Binda, R.M. Robinson, J.S. Martin Del Campo, N.D. Keul, P.J. Rodriguez, H. H. Robinson, A. Mattevi, P. Sobrado, An unprecedented NADPH domain

conformation in lysine monooxygenase NbtG provides insights into uncoupling of oxygen consumption from substrate hydroxylation, *J. Biol. Chem.* 290 (2015) 12676–12688.

[45] D.G. Fujimori, S. Hrvatin, C.S. Neumann, M. Stricker, M.A. Marahiel, C.T. Walsh, Cloning and characterization of the biosynthetic gene cluster for kutznerides, *Proc. Natl. Acad. Sci. U. S. A.* 104 (2007) 16498–16503.

[46] A.C. Campbell, R. Robinson, D. Mena-Aguilar, P. Sobrado, J.J. Tanner, Structural determinants of flavin dynamics in a class B monooxygenase, *Biochemistry* 59 (2020) 4609–4616.

[47] E. Romero, J.R. Gomez Castellanos, G. Gadda, M.W. Fraaije, A. Mattevi, Same substrate, many reactions: oxygen activation in flavoenzymes, *Chem. Rev.* 118 (2018) 1742–1769.

[48] G. Catucci, I. Zgrabllic, F. Lanciani, F. Valetti, D. Minerdi, D.P. Ballou, G. Gilardi, S.J. Sadeghi, Characterization of a new Baeyer–Villiger monooxygenase and conversion to a solely N- or S-oxidizing enzyme by a single R292 mutation, *Biochim. Biophys. Acta* 1864 (2016) 1177–1187.

[49] R.D. Bach, A. Mattevi, Mechanistic aspects regarding the elimination of H<sub>2</sub>O<sub>2</sub> from C(4a)-hydroperoxyflavin. The role of a proton shuttle required for H<sub>2</sub>O<sub>2</sub> elimination, *J. Org. Chem.* 78 (2013) 8585–8593.

[50] K. Thotsaporn, P. Chennprakhon, J. Sucharitakul, A. Mattevi, P. Chaiyen, Stabilization of C4a-hydroperoxyflavin in a two-component flavin-dependent monooxygenase is achieved through interactions at flavin N5 and C4a atoms, *J. Biol. Chem.* 286 (2011) 28170–28180.

[51] C. Tongsook, J. Sucharitakul, K. Thotsaporn, P. Chaiyen, Interactions with the substrate phenolic group are essential for hydroxylation by the oxygenase component of p-hydroxyphenylacetate 3-hydroxylase, *J. Biol. Chem.* 286 (2011) 44491–44502.

[52] M. Ortiz-Maldonado, D.P. Ballou, V. Massey, Use of free energy relationships to probe the individual steps of hydroxylation of p-hydroxybenzoate hydroxylase: studies with a series of 8-substituted flavins, *Biochemistry* 38 (1999) 8124–8137.

[53] H.M. Senn, S. Thiel, W. Thiel, Enzymatic hydroxylation in p-hydroxybenzoate hydroxylase: a case study for QM/MM molecular dynamics, *J. Chem. Theor. Comput.* 1 (2005) 494–505.

[54] B.A. Palfey, G.R. Moran, B. Entsch, D.P. Ballou, V. Massey, Substrate recognition by "password" in p-hydroxybenzoate hydroxylase, *Biochemistry* 38 (1999) 1153–1158.

[55] R.D. Bach, Role of the somersault rearrangement in the oxidation step for flavin monooxygenases (FMO). A comparison between FMO and conventional xenobiotic oxidation with hydroperoxides, *J. Phys. Chem.* 115 (2011) 11087–11100.

[56] L. Ridder, J.N. Harvey, I.M. Rietjens, J. Vervoort, A.J. Mulholland, Ab initio QM/MM modeling of the hydroxylation step in p-hydroxybenzoate hydroxylase, *J. Phys. Chem. B* 107 (2003) 2118–2126.

[57] B.A. Palfey, R. Basu, K.K. Frederick, B. Entsch, D.P. Ballou, Role of protein flexibility in the catalytic cycle of p-hydroxybenzoate hydroxylase elucidated by the Pro293Ser mutant, *Biochemistry* 41 (2002) 8438–8446.

[58] R.F. Anderson, K.B. Patel, B. Vojnovic, Absorption spectra of radical forms of 2, 4-dihydroxybenzoic acid, a substrate for p-hydroxybenzoate hydroxylase, *J. Biol. Chem.* 266 (1991) 13086–13090.

[59] R.F. Anderson, K.B. Patel, M. Stratford, Absorption spectra of radicals of substrates for p-hydroxybenzoate hydroxylase following electrophilic attack of the OH radical in the 3 position, *J. Biol. Chem.* 262 (1987) 17475–17479.

[60] R.M. Robinson, C.A. Klanchev, P.J. Rodriguez, P. Sobrado, Flavin oxidation in flavin-dependent N-monooxygenases, *Protein Sci.* 28 (2019) 90–99.

[61] S.E. Tweedy, A. Rodriguez Benitez, A.R. Narayan, P.M. Zimmerman, C. L. Brooks III, T. Wymore, Hydroxyl radical-coupled electron-transfer mechanism of flavin-dependent hydroxylases, *J. Phys. Chem. B* 123 (2019) 8065–8073.

[62] D.K. Chatterjee, W. Raether, N. Iyer, B.N. Ganguli, Caerulomycin, an antifungal antibiotic with marked in vitro and in vivo activity against *Entamoeba histolytica*, *Z. Parasitenkd.* 70 (1984) 569–573.

[63] J.M. Finefield, J.C. Frisvad, D.H. Sherman, R.M. Williams, Fungal origins of the bicyclo[2.2.2]diazaoctane ring system of prenylated indole alkaloids, *J. Nat. Prod.* 75 (2012) 812–833.

[64] S.M. Li, Prenylated indole derivatives from fungi: structure diversity, biological activities, biosynthesis and chemoenzymatic synthesis, *Nat. Prod. Rep.* 27 (2010) 57–78.

[65] T. Kotani, H. Yurimoto, N. Kato, Y. Sakai, Novel acetone metabolism in a propane-utilizing bacterium, *Gordonia* sp. strain TY-5, *J. Bacteriol.* 189 (2007) 886–893.

[66] M.N. Goettge, J.P. Cioni, K.-S. Ju, K. Pallitsch, W.W. Metcalf, PcxL and HpxL are flavin-dependent, oxime-forming N-oxidases in phosphonocystoxic acid biosynthesis in Streptomyces, *J. Biol. Chem.* 293 (2018) 6859–6868.

[67] S.A. Newmister, C.M. Gober, S. Romminger, F. Yu, A. Tripathi, L.L. Parra, R. M. Williams, R.G. Berlincck, M.M. Joullie, D.H. Sherman, OxAD: a versatile indolic nitrore synthase from the marine-derived fungus *Penicillium oxalicum* F30, *J. Am. Chem. Soc.* 138 (2016) 11176–11184.

[68] K.K.A. Wang, T.L. Ng, P. Wang, Z.D. Huang, E.P. Balskus, W.A. van der Donk, Glutamic acid is a carrier for hydrazine during the biosyntheses of fosfazinomycin and kinamycin, *Nat. Commun.* 9 (2018).

[69] F.F. Twigg, W. Cai, W. Huang, J. Liu, M. Sato, T.J. Perez, J. Geng, M.J. Dror, I. Montanez, T.L. Tong, H. Lee, W. Zhang, Identifying the biosynthetic gene cluster for triacsins with an N-hydroxytriazene moiety, *Chembiochem* 20 (2019) 1145–1149.

[70] C.L. Ventola, The antibiotic resistance crisis: part 1: causes and threats, *P T* 40 (2015) 277–283.

[71] G. Volkers, G.J. Palm, M.S. Weiss, G.D. Wright, W. Hinrichs, Structural basis for a new tetracycline resistance mechanism relying on the TetX monooxygenase, *FEBS Lett.* 585 (2011) 1061–1066.

[72] K. Walkiewicz, M. Davlieva, G. Wu, Y. Shamoo, Crystal structure of *Bacteroides thetaiotaomicron* TetX2, a tetracycline degrading monooxygenase at 2.8 Å resolution, *Proteins* 79 (2011), 2335.

[73] P. Rudra, K. Hurst-Hess, P. Lappierre, P. Ghosh, High levels of intrinsic tetracycline resistance in *Mycobacterium abscessus* are conferred by a tetracycline-modifying monooxygenase, *Antimicrobial agents and chemotherapy* 62, 2018.

[74] T. He, R. Wang, D. Liu, T.R. Walsh, R. Zhang, Y. Lv, Y. Ke, Q. Ji, R. Wei, Z. Liu, Emergence of plasmid-mediated high-level tigecycline resistance genes in animals and humans, *Nat. Microbiol.* 4 (2019) 1450–1456.

[75] Y. Hoshino, S. Fujii, H. Shinonaga, K. Arai, F. Saito, T. Fukai, H. Satoh, Y. Miyazaki, J. Ishikawa, Monooxygenation of rifampicin catalyzed by the rox gene product of *Novicardia farcinica*: structure elucidation, gene identification and role in drug resistance, *J. Antibiot.* 63 (2010) 23–28.

[76] L.-K. Liu, Y. Dai, H. Abdelwahab, P. Sobrado, J.J. Tanner, Structural evidence for rifampicin monooxygenase inactivating rifampicin by cleaving its ansa-bridge, *Biochemistry* 57 (2018) 2065–2068.

[77] L.-K. Liu, H. Abdelwahab, J.S.M. Del Campo, R. Mehra-Chaudhary, P. Sobrado, J. J. Tanner, The structure of the antibiotic deactivating, N-hydroxylating rifampicin monooxygenase, *J. Biol. Chem.* 291 (2016) 21553–21562.

[78] D. Minerdi, I. Zgrabllic, S. Castrignanò, G. Catucci, C. Medana, M.E. Terlizzi, G. Gribaldo, G. Gilardi, S.J. Sadeghi, *Escherichia coli* overexpressing a baeyer–villiger monooxygenase from *Acinetobacter radioresistens* becomes resistant to imipenem, *Antimicrob. Agents Chemother.* 60 (2016) 64–74.

[79] W.C. Hwang, Q. Xu, B. Wu, A. Godzik, Crystal structure of a baeyer–villiger flavin-containing monooxygenase from *Staphylococcus aureus* MRSA strain MU50, *Proteins* 86 (2018) 269.

[80] B. Ricken, B.A. Kolvenbach, C. Bergeschi, D. Benndorf, K. Kroll, H. Strnad, Č. Vlček, R. Adáiko, F. Hammes, P. Shahgaldian, FMNH 2-dependent monooxygenases initiate catabolism of sulfonamides in *Microbacterium* sp. strain BRI 1 subsisting on sulfonamide antibiotics, *Sci. Rep.* 7 (2017) 1–11.

[81] D.-W. Kim, C.N. Thawng, K. Lee, E.M. Wellington, C.-J. Cha, A novel sulfonamide resistance mechanism by two-component flavin-dependent monooxygenase system in sulfonamide-degrading actinobacteria, *Environ. Int.* 127 (2019) 206–215.

[82] J.R. Smith, J.F. Jamie, G.J. Guillemin, Kynurenone-3-monooxygenase: a review of structure, mechanism, and inhibitors, *Drug Discov. Today* 21 (2016) 315–324.

[83] S. Zhang, M. Sakuma, G.S. Deora, C.W. Levy, A. Klausing, C. Breda, K.D. Read, C. D. Edlin, B.P. Ross, M.W. Muelas, A brain-permeable inhibitor of the neurodegenerative disease target kynurenone 3-monooxygenase prevents accumulation of neurotoxic metabolites, *Commun. Biol.* 2 (2019) 1–10.

[84] D.J. Mole, S.P. Webster, I. Uings, X. Zheng, M. Binnie, K. Wilson, J.P. Hutchinson, O. Mirgut, A. Walker, B. Beaufils, Kynurenone-3-monooxygenase inhibition prevents multiple organ failure in rodent models of acute pancreatitis, *Nat. Med.* 22 (2016) 202.

[85] J.P. Hutchinson, P. Rowland, M.R. Taylor, E.M. Christodoulou, C. Haslam, C. I. Hobbs, D.S. Holmes, P. Homes, J. Liddle, D.J. Mole, Structural and mechanistic basis of differentiated inhibitors of the acute pancreatitis target kynurenone-3-monooxygenase, *Nat. Commun.* 8 (2017) 1–12.

[86] K. Jacobs, G. Guillemin, D. Lovejoy, Development of a rapid fluorescence-based high-throughput screening assay to identify novel kynurenone 3-monooxygenase inhibitor scaffolds, *SLAS Discovery: Adv. Life Sci. R&D* 23 (2018) 554–560.

[87] R.S. Phillips, E.C. Iradukunda, T. Hughes, J.P. Bowen, Modulation of enzyme activity in the kynurenone pathway by kynurenone monooxygenase inhibition, *Front. Mole. Biosci.* 6 (2019) 3.

[88] K.R. Crozier-Reabe, R.S. Phillips, G.R. Moran, Kynurenone 3-monooxygenase from *Pseudomonas fluorescens*: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin–peroxy intermediate yet result in the production of hydrogen peroxide, *Biochemistry* 47 (2008) 12420–12433.

[89] A.J. Brown, N.K. Chua, N. Yan, The shape of human squalene epoxidase expands the arsenal against cancer, *Nat. Commun.* 10 (2019) 1–4.

[90] A.K. Padyana, S. Gross, L. Jin, G. Cianchetta, R. Narayanaswamy, F. Wang, R. Wang, C. Fang, X. Lv, S.A. Biller, Structure and inhibition mechanism of the catalytic domain of human squalene epoxidase, *Nat. Commun.* 10 (2019) 1–10.

[91] C.E. Mahoney, D. Pirman, V. Chubukov, T. Sleger, S. Hayes, Z.P. Fan, E.L. Allen, Y. Chen, L. Huang, M. Liu, Y. Zhang, G. McDonald, R. Narayanaswamy, S. Choe, Y. Chen, S. Gross, G. Cianchetta, A.K. Padyana, S. Murray, W. Liu, K.M. Marks, J. Murtie, M. Dorsch, S. Jin, N. Nagaraja, S.A. Biller, T. Roddy, J. Popovici-Muller, G.A. Smolen, A chemical biology screen identifies a vulnerability of neuroendocrine cancer cells to SQLE inhibition, *Nat. Commun.* 10 (2019) 96.

[92] J. Song, N. Shang, N. Baig, J. Yao, C. Shin, B.K. Kim, Q. Li, S.R. Malwal, E. Oldfield, X. Feng, *Aspergillus flavus* squalene synthase as an antifungal target: expression, activity, and inhibition, *Biochem. Biophys. Res. Commun.* 512 (2019) 517–523.

[93] J.S. Martín del Campo, N. Vogelaar, K. Tolani, K. Kizjakina, K. Harich, P. Sobrado, Inhibition of the flavin-dependent monooxygenase siderophore A (SidA) blocks siderophore biosynthesis and *Aspergillus fumigatus* growth, *ACS Chem. Biol.* 11 (2016) 3035–3042.

[94] K.M. Meneely, A.L. Lamb, Biochemical characterization of a flavin adenine dinucleotide-dependent monooxygenase, ornithine hydroxylase from *Pseudomonas aeruginosa*, suggests a novel reaction mechanism, *Biochemistry* 46 (2007) 11930–11937.

[95] J. Park, A.J. Gasparrini, M.R. Reck, C.T. Symister, J.L. Elliott, J.P. Vogel, T. A. Wencewicz, G. Dantas, N.H. Tolia, Plasticity, dynamics, and inhibition of emerging tetracycline resistance enzymes, *Nat. Chem. Biol.* 13 (2017) 730.

[96] P. Wang, G. Bashiri, X. Gao, M.R. Sawaya, Y. Tang, Uncovering the enzymes that catalyze the final steps in oxytetracycline biosynthesis, *J. Am. Chem. Soc.* 135 (2013) 7138–7141.

[97] I. Saraav, K. Pandey, R. Misra, S. Singh, M. Sharma, S. Sharma, Characterization of MymA protein as a flavin-containing monooxygenase and as a target of isoniazid, *Chem. Biol. Drug Des.* 89 (2017) 152–160.

[98] A.L. Moure, G. Narula, F. Sorrentino, A. Bojang, C.K. Tsui, C. Sao Emani, E. Porras-De Francisco, B. Díaz, M.J. Rebollo-López, P.A. Torres-Gómez, MymA bioactivated thioalkylbenzoxazole prodrug family active against *Mycobacterium tuberculosis*, *J. Med. Chem.* 63 (2020) 4732–4748.

[99] M. Schorn, J. Zettler, J.P. Noel, P.C. Dorrestein, B.S. Moore, L. Kaysser, Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors, *ACS Chem. Biol.* 9 (2014) 301–309.

[100] R.J. Glenn, A.J. Pemberton, H.J. Royle, R.W. Spackman, E. Smith, A. Jennifer Rivett, D. Steverding, Trypanocidal effect of alpha',beta'-epoxyketones indicates that trypanosomes are particularly sensitive to inhibitors of proteasome trypsin-like activity, *Int. J. Antimicrob. Agents* 24 (2004) 286–289.

[101] D. Zabala, J.W. Cartwright, D.M. Roberts, B.J. Law, L. Song, M. Samborsky, P. F. Leadlay, J. Micklefield, G.L. Challis, A flavin-dependent decarboxylase-dehydrogenase-monoxygenase assembles the warhead of  $\alpha$ ,  $\beta$ -epoxyketone proteasome inhibitors, *J. Am. Chem. Soc.* 138 (2016) 4342–4345.

[102] P.F. Fitzpatrick, Insights into the mechanisms of flavoprotein oxidases from kinetic isotope effects, *J. Label. Compd. Radiopharm.* 50 (2007) 1016–1025.

[103] E. Romero, G. Gadda, Alcohol oxidation by flavoenzymes, *Biomol. Concepts* 5 (2014) 299–318.

[104] I. Lans, M. Medina, E. Rosta, G. Hummer, M. Garcia-Viloca, J.M. Lluch, A. Gonzalez-Lafont, Theoretical study of the mechanism of the hydride transfer between ferredoxin-NADP $^{+}$  reductase and NADP $^{+}$ : the role of Tyr303, *J. Am. Chem. Soc.* 134 (2012) 20544–20553.

[105] Z. Deng, A. Aliverti, G. Zanetti, A.K. Arakaki, J. Ottado, E.G. Orellano, N. B. Calcaterra, E.A. Ceccarelli, N. Carrillo, P.A. Karplus, A productive NADP $^{+}$  binding mode of ferredoxin-NADP $^{+}$  reductase revealed by protein engineering and crystallographic studies, *Nat. Struct. Biol.* 6 (1999) 847–853.

[106] N. Carrillo, E.A. Ceccarelli, Open questions in ferredoxin-NADP $^{+}$  reductase catalytic mechanism, *Eur. J. Biochem./FEBS* 270 (2003) 1900–1915.